News Amgen Inc.

Stocks

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-30 EDT			5-day change	1st Jan Change
421.51 ^USD	-0.50%		+3.80%	+28.78%

09-30	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT

All News

Mentions Relevance

09-28	Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept	MT
09-25	Mesirow Financial Investment Management, Inc. acquired office complex in Deerfield from Amgen Inc. (NasdaqGS : AMGN) for $151 million.	CI
09-23	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJOGREN'S DISEASE	AQ
09-23	Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating	MT
09-22	Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-To-Severe Systemic Sjögren's Disease	CI
09-22	Amgen Says Phase 3 Dazodalibep Trial Shows Systemic Disease Activity Improvement in Sjogren's Disease	MT
09-22	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE	PR
09-22	Amgen's autoimmune drug succeeds in late-stage trial	RE
09-16	Sling Therapeutics raises $123 million to advance thyroid eye disease drug	RE
09-15	Amgen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
09-14	Amgen Gets FDA Approval to Reduce Monitoring Time for First Two Imdelltra Doses	MT
09-14	FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®	PR
09-14	Amgen Receives FDA Approval for Reduced Monitoring Time for First Two Doses of Imdelltra	CI
09-11	Dublin residents have mixed feelings ahead of Trump visit to Ireland	RE
09-10	Amgen Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-10-2026 11:00 AM
09-10	FTC Updates (August 17-21, 24-28)	AQ
09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-09	AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	PR
09-08	Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial	RE
09-08	Top Midday Decliners	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Amgen caught in the crossfire of Novartis' failure
09-08	Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer	MT
09-08	Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone	CI
09-08	Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial	RE